03:30 PM EDT, 05/29/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Following NDSN's Apr-Q earnings beat, we lower our target to $220 from $235, valuing shares at 20.5x our FY 26 (Oct.) EPS of $10.75 (up from $10.40; FY 25 EPS to $9.89 from $9.78). Recent manufacturing data (April ISM PMI at 48.7, core capital goods orders down 1.3%) reinforces our cautious stance on industrial equipment spending. Management indicates destocking pressures are gradually easing, with sequential improvements in order entry for medical interventional product lines. The Court of International Trade's ruling blocking most tariffs creates uncertainty, though NDSN has implemented pricing and supply chain adjustments to offset modest tariff costs. We estimate revenues to be up 3% in FY 25, followed by 5% growth in FY 26, with gross margin rising 60 bps to 55.8% in FY 25 and expanding another 50 bps in FY 26 to 56.3%, reflecting improving factory efficiencies and growth in higher-margin product lines. The Atrion acquisition's strong performance validates NDSN's disciplined M&A approach.